Biosearch Life signs an agreement with Angelini pharmaceutical, S.A. for the marketing in Hereditum ® Lc40 Spain for the treatment of mastitis in lactating women
Biosearch Life signs an agreement with Angelini pharmaceutical, S.A. for the marketing in Hereditum ® Lc40 Spain for the treatment of mastitis in lactating women – a preventive and curative treatment to mastitis – inflammation of the chest associated with the breastfeeding-a disease that is the leading medical cause of the early abandonment of the practice recommended by the who is -strains of the range Hereditum ®, the only ones from breast milk, have been selected among hundreds for their excellent skills and its scientifically proven beneficial effects Madrid, may of 2012- Biosearch Life, biotechnology company of reference in the world of healthy ingredients, has announced the signing of a license and agreement exclusive distribution with Angelini pharmaceutical marketing in the Spanish market of Hereditum ® Lactobacillus Fermentum Lc40 oriented preventive and curative treatment of mastitis in lactating women. we are very pleased by the signing of this agreement with Angelini pharmaceutical and insurance that the fruit of this collaboration will be an invaluable help for nursing mothers and health of their infants. During recent years we have worked very hard on this project, so it makes us especially excited to move it to the market and offer another innovative solution designed to maintain and improve the health of people ”, says Jose Mª Roset, Director General of Biosearch Life. Collaboration with Angelini will help us to further consolidate...
Read More